|
|
|
|
Trial | Studied trt | Control trt | patients | tags | ROB | Trial result | Major bleeding | All cause death |
---|
|
|
MERLIN TIMI 36, 2007 NCT | ranolazine | placebo | | | Low risk of bias | suggesting | | |
|
|
APPRAISE-1 (10mg od), 2009 NCT | apixaban | placebo | | | Low risk of bias | negative | | |
APPRAISE-1 (2.5 mg bid), 2009 NCT | apixaban | placebo | | | Low risk of bias | negative | | |
APPRAISE 2, 2011 NCT | apixaban | placebo | | | Low risk of bias | negative | | |
|
ASPECT-2 (coumadin+asp vs asp), 2002 | coumadin | control (on top of aspirin) | | | | suggesting | | |
ASPECT-2 (coumadin vs aspirin), 2002 | coumadin | aspirin | | | | suggesting | | |
|
REDEEM, 2009 NCT | dabigatran | placebo | | | Low risk of bias | negative | | |
|
SEPIA-ACS1 TIMI 42, 2009 NCT | otamixaban | unfractionated heparin | | | Low risk of bias | suggesting | | |
|
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011 NCT | rivaroxaban 2.5mg | placebo | | | Low risk of bias | suggesting | | |
ATLAS ACS-TIMI 46 (2.5mg), 2009 NCT | rivaroxaban 2.5mg | placebo | | | Low risk of bias | negative | | |
ATLAS ACS 2 - TIMI 51 (5mg), 2011 NCT | rivaroxaban 5mg | placebo | | | | suggesting | | |
ATLAS ACS-TIMI 46 (5mg), 2009 NCT | rivaroxaban 5mg | placebo | | | Low risk of bias | negative | | |
|
ATACS (pilot study) (warfarin vs control), 1990 | warfarin | control (on top of aspirin) | | | | negative | | |
ATACS, 1994 | warfarin | control (on top of aspirin) | | | | negative | | |
CARS, 1997 | warfarin | control (on top of aspirin) | | | | negative | | |
OASIS Pilot (phase 1), 1998 | warfarin | control (on top of aspirin) | | | | negative | | |
OASIS Pilot (phase 2), 1998 | warfarin | control (on top of aspirin) | | | | negative | | |
OASIS-2 Warfarin Substudy, 2001 | warfarin | control (on top of aspirin) | | | | negative | | |
APRICOT-2, 2002 | warfarin | control (on top of aspirin) | | | | negative | | |
CHAMP, 2002 | warfarin | control (on top of aspirin) | | | | negative | | |
WARIS, 2002 | warfarin | control (on top of aspirin) | | | | suggesting | | |
LoWASA, 2004 | warfarin | control (on top of aspirin) | | | | negative | | |
Zibaeenezhad, 2004 | warfarin | control (on top of aspirin) | | | | negative | | |
Williams, 1997 | warfarin | placebo (on top of aspirin) | | | Low risk of bias | negative | | |
Huyhn, 2001 | warfarin | placebo (on top of aspirin) | | | Low risk of bias | negative | | |
ATACS (pilot study) warfarin vs aspirin, 1990 | warfarin | aspirin | | | | negative | | |
|
ESTEEM, 2003 | ximelagatran | placebo | | | Exploratory | - | | |
|
|
Jones, 1987 | dazoxiben | control | | | | negative | | |
GRAND, 1987 | GR3219B | control | | | | negative | | |
Gent-AMI, 1968 | misc. | control | | | | negative | | |
Johannessen, 1989 | misc. | control | | | | negative | | |
French, 1993 | flurbiprofen | placebo | | | Low risk of bias | suggesting | | |
CURRENT - OASIS 7 (ASA), 2010 NCT | ASA high dose | ASA low dose | | | Risk of bias | suggesting | | |
|
ATACS-pilot, 1990 | aspirin | control | | | | negative | | |
Huddinge, 1988 | aspirin | control | | | | negative | | |
Frankfurt, 1976 | aspirin | control | | | | negative | | |
VA-pilot | aspirin | placebo | | | | negative | | |
VA-main, 1983 | aspirin | placebo | | | Low risk of bias | suggesting | | |
RISC, 1990 | aspirin | placebo | | | Low risk of bias | suggesting | | |
ALDUSA-pilot | aspirin | placebo | | | | negative | | |
Théroux, 1988 | aspirin | placebo | | | Low risk of bias | suggesting | | |
Canadian (Aspirin vs PBO), 1985 | aspirin | placebo | | | Low risk of bias | - | | |
Dutch-aspirin, 1990 | aspirin | placebo | | | Low risk of bias | negative | | |
ISIS-pilot, 1987 | aspirin | placebo | | | Low risk of bias | negative | | |
ISIS-2, 1988 | aspirin | placebo | | | Low risk of bias | suggesting | | |
APRICOT, 1993 | aspirin | placebo | | | Low risk of bias | suggesting | | |
Canadian (Aspirin + sulfinpyrazone), 1985 | aspirin + sulfinpyrazone | placebo | | | Low risk of bias | negative | | |
|
J-LANCELOT, 2010 | atopaxar | placebo | | | Exploratory | - | | |
LANCELOT ACS | atopaxar | placebo | | | Exploratory | - | | |
|
COMMIT, 2005 NCT | clopidogrel | placebo | | | Low risk of bias | suggesting | | |
CLARITY-TIMI 28, 2005 | clopidogrel | placebo | | | Low risk of bias | - | | |
CURE, 2001 | clopidogrel + aspirin | aspirin | | | Low risk of bias | suggesting | | |
CURRENT OASIS 7 (clopidogrel), 2010 NCT | clopidogrel high-dose regimen | clopidogrel standard-dose | | | Low risk of bias | negative | | |
|
Prandoni, 1991 | aspirin + dipyridamol | placebo | | | Low risk of bias | negative | | |
|
ERASE-MI, 2009 | elinogrel | placebo | | | Low risk of bias | negative | | |
|
TRILOGY ACS (overall population), 2012 NCT | prasugrel | clopidogrel | | | Low risk of bias | negative | | |
TRITON-TIMI 38, 2007 NCT | prasugrel | clopidogrel | | | Low risk of bias | suggesting | | |
|
Dutch sulphinpyrazone, 1986 | sulfinpyrazone | control | | | | negative | | |
Canadian (sulfinpyrazone alone), 1985 | sulfinpyrazone | placebo | | | Low risk of bias | - | | |
Wilcox, 1980 | sulfinpyrazone | placebo | | | | negative | | |
Louvain sulphinpyrazone, 1983 | sulfinpyrazone | placebo | | | Low risk of bias | negative | | |
|
PLATO, 2009 NCT | ticagrelor | clopidogrel | | | Low risk of bias | suggesting | | |
DISPERSE-2 (90mg), 2007 | ticagrelor | clopidogrel | | | Low risk of bias | negative | | |
|
STAI, 1990 | ticlopidine | control | | | | suggesting | | |
Knudsen-A, 1985 | ticlopidine | control | | | | negative | | |
Florida UA | ticlopidine | placebo | | | | negative | | |
|
Modena | trapidil | placebo | | | | suggesting | | |
|
Plaza, 1993 | triflusal | placebo | | | Low risk of bias | suggesting | | |
|
TRACER, 2011 NCT | vorapaxar | placebo (on top standard therapy) | | | Low risk of bias | - | | |
|
|
Gurfinkel (LMWH+asp vs asp), 1995 | LMWH | placebo (on top of aspirin) | | | | suggesting | | |
CURRENT - OASIS 7 (ASA), 2010 NCT | ASA high dose | ASA low dose | | | Risk of bias | suggesting | | |
Gurfinkel (LMWH+asp vs UFH+asp), 1995 | LMWH | UFH (on top of aspirin) | | | | suggesting | | |
|
APPRAISE-1 (10mg od), 2009 NCT | apixaban | placebo | | | Low risk of bias | negative | | |
APPRAISE-1 (2.5 mg bid), 2009 NCT | apixaban | placebo | | | Low risk of bias | negative | | |
APPRAISE 2, 2011 NCT | apixaban | placebo | | | Low risk of bias | negative | | |
|
ARGAMI-2, 1998 | Argatroban | heparin | | | | - | | |
|
ATACS-pilot, 1990 | aspirin | control | | | | negative | | |
VA-pilot | aspirin | placebo | | | | negative | | |
VA-main, 1983 | aspirin | placebo | | | Low risk of bias | suggesting | | |
RISC, 1990 | aspirin | placebo | | | Low risk of bias | suggesting | | |
ALDUSA-pilot | aspirin | placebo | | | | negative | | |
Théroux, 1988 | aspirin | placebo | | | Low risk of bias | suggesting | | |
Canadian (Aspirin vs PBO), 1985 | aspirin | placebo | | | Low risk of bias | - | | |
Canadian (Aspirin + sulfinpyrazone), 1985 | aspirin + sulfinpyrazone | placebo | | | Low risk of bias | negative | | |
|
LANCELOT ACS | atopaxar | placebo | | | Exploratory | - | | |
J-LANCELOT, 2010 | atopaxar | placebo | | | Exploratory | - | | |
|
ACUITY (biva alone vs hep+aGP2b3a), 2006 NCT | bivalirudin | heparin + GP2b3a inhibitors | | | Low risk of bias | suggesting | | |
ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006 NCT | bivalirudin + GP2b3a inhibitors | heparin + GP2b3a inhibitors | | | Low risk of bias | negative | | |
PROTECT-TIMI 30, 2006 NCT | bivalirudin | eptifibatide + heparin | | | Exploratory | - | | |
HERO, 1997 | bivalirudin | heparin | | | Low risk of bias | suggesting | | |
BAT (Bittl), 1995 | bivalirudin | heparin | | | Low risk of bias | suggesting | | |
ACUITY (sub groups PCI, bivalirudin alone) importé, 2007 | bivalirudin | heparin + GP2b3a inhibitors | | | | suggesting | | |
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007 | bivalirudin + GP2b3a inhibitors | heparin + GP2b3a inhibitors | | | | negative | | |
|
CURE (PCI sub study), 2001 | clopidogrel | placebo | | | Low risk of bias | - | | |
CURE, 2001 | clopidogrel + aspirin | aspirin | | | Low risk of bias | suggesting | | |
CURRENT OASIS 7 (clopidogrel), 2010 NCT | clopidogrel high-dose regimen | clopidogrel standard-dose | | | Low risk of bias | negative | | |
|
ASPECT-2 (coumadin+asp vs asp), 2002 | coumadin | control (on top of aspirin) | | | | suggesting | | |
ASPECT-2 (coumadin vs aspirin), 2002 | coumadin | aspirin | | | | suggesting | | |
|
FRISC (long term), 1996 | dalteparin | placebo (on top of aspirin) | | | Low risk of bias | suggesting | | |
FRIC prolonged treatment phase (LWMH vs PBO), 1997 | dalteparin | placebo (on top of aspirin) | | | Low risk of bias | negative | | |
FRISC (short term), 1996 | dalteparin | placebo (on top of aspirin) | | | Low risk of bias | - | | |
FRIC (acute phase LMWH vs UFH), 1997 | dalteparin | UFH (on top of aspirin) | | | Exploratory | negative | | |
|
Prandoni, 1991 | aspirin + dipyridamol | placebo | | | Low risk of bias | negative | | |
|
Klootwijk, 1999 | Efegatran | heparin | | | Exploratory | - | | |
|
RESCUE NCT | enoxaparin | unfractionated heparin | | | | - | | |
EVET, 2005 | enoxaparin | tinzaparin | | | | suggesting | | |
ESSENCE, 1997 | enoxaparin | UFH (on top of aspirin) | | | Low risk of bias | suggesting | | |
|